<p>Sino Biopharmaceutical Limited has announced the completion of subject enrollment in a Phase III clinical trial of its investigational drug TQB2102, a HER2 bispecific antibody-drug conjugate (ADC), for the treatment of HER2-low recurrent or metastatic breast cancer. The trial, titled “Randomised, Open-label, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-selected Chemotherapy in HER2-Low Recurrent/Metastatic Breast Cancer (TQB2102-III-01),” aims to assess the efficacy and safety of TQB2102 compared to standard chemotherapy options. TQB2102 is described as a next-generation HER2 dual-epitope bispecific ADC developed by the company. Results from this Phase III trial have not yet been presented. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260210-12019960), on February 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

<p>Sino Biopharmaceutical Limited has completed enrollment for a Phase III clinical trial of TQB2102, a HER2 bispecific antibody-drug conjugate, targeting HER2-low recurrent or metastatic breast cancer. The trial, named TQB2102-III-01, will compare the efficacy and safety of TQB2102 against standard chemotherapy. Results are pending. This announcement was published via the Hong Kong Stock Exchange.</p>

Reuters

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng Health Care ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Huaan Hang Seng Biotech ETF

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua CSI HK Connect Health Care Composite ETF

SINO BIOPHARM

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai SSE STAR Brand Name Drug ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Universal 800 Health Care ETF

Sino Biopharm Completes Enrollment for Phase III Trial of HER2 Bispecific ADC in HER2-Low Breast Cancer